(Q81090446)

English

A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy

scientific article published on 01 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1 reference

Europe PubMed Central

A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

P L Bergsagel

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 April 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

673-675

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18414492%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

https://scigraph.springernature.com/pub.10.1038/leu.2008.2

0 references

Suppression of abnormal karyotype predicts superior survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

The molecular classification of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dysimmunoglobulinemia in the absence of clinical features of multiple myeloma and macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple myeloma: evolving genetic events and host interactions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81090446&oldid=1721494371"